June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Long-term Outcome of Conventional and Half-fluence Photodynamic Theraphy for Chronic Central Serous Chorioretinopathy
Author Affiliations & Notes
  • BoKwon Son
    Kyung Hee University Hospital, Seoul, Korea (the Republic of)
  • Eung-Suk Kim
    Kyung Hee University Hospital, Seoul, Korea (the Republic of)
  • Seung-Young Yu
    Kyung Hee University Hospital, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   BoKwon Son, None; Eung-Suk Kim, None; Seung-Young Yu, Allergan (F), Bayer (F), Norvatis (F), Zeiss (F)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4675. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      BoKwon Son, Eung-Suk Kim, Seung-Young Yu; Long-term Outcome of Conventional and Half-fluence Photodynamic Theraphy for Chronic Central Serous Chorioretinopathy
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):4675.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the long-term efficacy and safety of conventional photodynamic therapy (PDT) and half-fluence PDT in chronic central serous chorioretinopathy (CSC)

Methods : Retrospective review of chronic CSC patients treated with conventional PDT or half-fluence PDT and a minimum follow-up of 12 months between October 2007 and June 2015. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), neural retinal thickness (NRT), choroidal thickness (CT), recurrence of CSC after PDT and resolution of subretinal fluid (SRF) at 12, 24 and 36 months were assessed.

Results : The study included 52 eyes completed the 36-month follow-up. 28 eyes received conventional PDT and 24 eyes received half-fluence PDT. The mean follow-up period was 45 months. The mean logMAR BCVA improved significantly (P < .001), both in the conventional group (from 0.36±0.32 to 0.15±0.27) and in the half-fluence group (from 0.31±0.29 to 0.15±0.28) at 36 months, without significant difference between the 2 groups (p=0.711). The mean CRT decreased significantly (P < .001), both in the conventional group (from 395.2±185 to 205.2±45.8) and in the half-fluence group (from 341.8±97.9 to 205.6±50.1), at 36 months, without significant difference between the 2 groups (p=0.362). Both groups showed significant reduction in CT at months 36 after PDT with significant difference (p<0.001). At 36 months, all patients in the both groups had complete absorption of subretinal fluid (SRF). There were no recurrence of SRF during the follow-up.

Conclusions : Both treatments were effective and safe in chronic central serous chorioretinopathy treatment with a significant improvement in the long term, both anatomic and visual, without recurrence of SRF.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×